Smith & Nephew plc (NYSE:SNN) Declares Semi-annual Dividend of $0.29

Smith & Nephew plc (NYSE:SNN) announced a semi-annual dividend on Monday, July 1st, NASDAQ reports. Investors of record on Friday, October 4th will be paid a dividend of 0.288 per share by the medical equipment provider on Friday, November 8th. This represents a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, October 4th. This is an increase from Smith & Nephew’s previous semi-annual dividend of $0.24.

Smith & Nephew has a dividend payout ratio of 28.0% meaning its dividend is sufficiently covered by earnings. Analysts expect Smith & Nephew to earn $2.07 per share next year, which means the company should continue to be able to cover its $0.58 annual dividend with an expected future payout ratio of 28.0%.

Smith & Nephew Stock Performance

Shares of SNN opened at $30.81 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The firm has a 50 day moving average of $30.46 and a 200 day moving average of $27.25. Smith & Nephew has a twelve month low of $21.52 and a twelve month high of $31.72.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on SNN. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 5th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Smith & Nephew in a report on Wednesday, July 24th. They issued a “buy” rating on the stock. Finally, UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a report on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.